Brett Monia, Ionis Pharmaceuticals CEO
Ionis hands off an antisense drug for kidney disease, giving all rights to Roche
Ionis is handing Roche a drug on the cusp of Phase III.
Ionis announced early Monday that Roche is in-licensing and advancing the antisense drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
